Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents

Sinovac Life Sciences Co., Ltd.31,041 enrolled

Overview

This study is a multi-center and open design, phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this study is to evaluate the safety of the SARS-CoV-2 Inactivated vaccine in population aged 3\~17 years and in people with pre-existing disease to provide reference for improving the immunization strategy of COVID-19 vaccine.

This study is a multi-center and open design, phase Ⅳ clinical trial in population aged 3\~17 years . The experimental vaccine will be manufactured by Sinovac Research and Development Co.,Ltd.The study is planned to be carried out in 11 provinces from August 2021 to December 2022, including Liaoning, Heilongjiang, Anhui, Fujian, Jiangxi, Hubei, Guangxi, Chongqing, Guizhou, Yunnan and Gansu. Each province will serve as a research center, and each research center will select the corresponding research site.A total of 33000 subjects including patients with pre-existing will be enrolled with 3000 for each research center, including 600 subjects aged 3\~5years，1200 subjects aged 6\~11 years,1200 subjects aged 12\~17 years. And subjects will receive two doses of vaccine on day 0 and day 28.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

31,041

Conditions

COVID-19

Interventions

Experimental GroupBIOLOGICAL

SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection

Eligibility

Sex: ALLMin age: 3 YearsMax age: 17 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Have not received any COVID-19 vaccine in the past or at least one dose of CoronaVac manufactured by Sinovac Research and Development Co.,Ltd; * Population aged 3\~17 years ; * The subjects can understand and voluntarily sign the informed consent form and participate in the follow-up; Exclusion Criteria: * History of severe allergy to the vaccine such as acute allergic reaction,angioedema and dyspnea ; * Severe neurological disease such as Myelitis transverse,Guillain-Barre Syndrome and demyelinating disorders; * Acute disease,acute onset of chronic disease and severe chronic diseases.

Locations (1)

Yongping Center for Diseases Control and Prevention

Dali, Yunnan, China

Outcomes

Primary Outcomes

Safety index 1-incidence of adverse reactions

Incidence rate of adverse reactions within 0\~7 days after each dose in all populations.

Time frame: Within 0~7 days after each dose

Secondary Outcomes

Safety index 2-incidence of adverse reactions

Incidence rate of adverse reactions within 0\~28 days after each dose in all populations

Time frame: Within 0-28 days after each dose vaccination

Safety index 3-incidence of adverse reactions

Incidence of adverse reactions within 0\~7 days after each dose in each age group

Time frame: Within 0~7 days after each dose vaccination

Safety index 4-incidence of adverse reactions

Incidence rate of adverse reactions within 0\~28 days after each dose in each age group

Time frame: Within 0~28 days after each dose vaccination

Safety index 5-incidence of adverse reactions

Incidence of adverse reactions within 0\~7 days after each dose in the population with pre-existing disease.

Time frame: Within 0~7 days after each dose vaccination

Safety index 6-incidence of adverse reactions

Incidence of adverse reactions within 0\~28 days after each dose in the population with pre-existing disease.

Time frame: Within 0~28 days after each dose vaccination

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.